BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 21914088)

  • 1. Temporal changes in salivary glands of non-obese diabetic mice as a model for Sjögren's syndrome.
    Roescher N; Lodde BM; Vosters JL; Tak PP; Catalan MA; Illei GG; Chiorini JA
    Oral Dis; 2012 Jan; 18(1):96-106. PubMed ID: 21914088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Injection of CD40 DNA vaccine ameliorates the autoimmune pathology of non-obese diabetic mice with Sjögren's syndrome.
    Zhou YB; Yuan X; Wang QK; Zhang H; Wang GS; Li XP; Wang Y; Harris D; Li XM
    Immunol Lett; 2020 Oct; 226():62-70. PubMed ID: 32707129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockade of CD40-CD154 pathway interactions suppresses ectopic lymphoid structures and inhibits pathology in the NOD/ShiLtJ mouse model of Sjögren's syndrome.
    Wieczorek G; Bigaud M; Pfister S; Ceci M; McMichael K; Afatsawo C; Hamburger M; Texier C; Henry M; Cojean C; Erard M; Mamber N; Rush JS
    Ann Rheum Dis; 2019 Jul; 78(7):974-978. PubMed ID: 30902822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired salivary gland function in NOD mice: association with changes in cytokine profile but not with histopathologic changes in the salivary gland.
    Jonsson MV; Delaleu N; Brokstad KA; Berggreen E; Skarstein K
    Arthritis Rheum; 2006 Jul; 54(7):2300-5. PubMed ID: 16802370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-120-kDa alpha-fodrin immune response with Th1-cytokine profile in the NOD mouse model of Sjögren's syndrome.
    Yanagi K; Ishimaru N; Haneji N; Saegusa K; Saito I; Hayashi Y
    Eur J Immunol; 1998 Oct; 28(10):3336-45. PubMed ID: 9808203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agonist-induced 4-1BB activation prevents the development of Sjӧgren's syndrome-like sialadenitis in non-obese diabetic mice.
    Zhou J; You BR; Yu Q
    Biochim Biophys Acta Mol Basis Dis; 2020 Mar; 1866(3):165605. PubMed ID: 31740402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local delivery of AAV2-CTLA4IgG decreases sialadenitis and improves gland function in the C57BL/6.NOD-Aec1Aec2 mouse model of Sjögren's syndrome.
    Yin H; Nguyen CQ; Samuni Y; Uede T; Peck AB; Chiorini JA
    Arthritis Res Ther; 2012 Feb; 14(1):R40. PubMed ID: 22369699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin improves salivary gland inflammation and hypofunction in murine Sjögren's syndrome.
    Kim JW; Kim SM; Park JS; Hwang SH; Choi J; Jung KA; Ryu JG; Lee SY; Kwok SK; Cho ML; Park SH
    Arthritis Res Ther; 2019 Jun; 21(1):136. PubMed ID: 31164166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salivary gland changes in the NOD mouse model for Sjögren's syndrome: is there a non-immune genetic trigger?
    Humphreys-Beher MG; Yamachika S; Yamamoto H; Maeda N; Nakagawa Y; Peck AB; Robinson CP
    Eur J Morphol; 1998 Aug; 36 Suppl():247-51. PubMed ID: 9825931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New concepts for the development of autoimmune exocrinopathy derived from studies with the NOD mouse model.
    Humphreys-Beher MG; Peck AB
    Arch Oral Biol; 1999 May; 44 Suppl 1():S21-5. PubMed ID: 10414851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Progress in understanding the pathogenesis of Sjögren's syndrome in non-obese diabetic mice].
    Su YC; Wu LL; Xiang RL
    Sheng Li Ke Xue Jin Zhan; 2012 Jun; 43(3):171-6. PubMed ID: 23019918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TACI-Fc gene therapy improves autoimmune sialadenitis but not salivary gland function in non-obese diabetic mice.
    Vosters JL; Roescher N; Illei GG; Chiorini JA; Tak PP
    Oral Dis; 2012 May; 18(4):365-74. PubMed ID: 22212434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-IL-7 receptor-α treatment ameliorates newly established Sjögren's-like exocrinopathy in non-obese diabetic mice.
    Zhou J; Yu Q
    Biochim Biophys Acta Mol Basis Dis; 2018 Jul; 1864(7):2438-2447. PubMed ID: 29680668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose interleukin-2 can improve salivary secretion but not lymphocyte infiltration of salivary glands in a murine model of Sjögren's syndrome.
    Wen J; Zhu F; Yu X; Xie H; Li C
    BMC Immunol; 2022 Oct; 23(1):49. PubMed ID: 36244973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local expression of tumor necrosis factor-receptor 1:immunoglobulin G can induce salivary gland dysfunction in a murine model of Sjögren's syndrome.
    Vosters JL; Yin H; Roescher N; Kok MR; Tak PP; Chiorini JA
    Arthritis Res Ther; 2009; 11(6):R189. PubMed ID: 20003451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD40 on salivary gland epithelial cells: high constitutive expression by cultured cells from Sjögren's syndrome patients indicating their intrinsic activation.
    Dimitriou ID; Kapsogeorgou EK; Moutsopoulos HM; Manoussakis MN
    Clin Exp Immunol; 2002 Feb; 127(2):386-92. PubMed ID: 11876766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salivary-gland-protective regulatory T-cell dysfunction underlies female-specific sialadenitis in the non-obese diabetic mouse model of Sjögren syndrome.
    Barr JY; Wang X; Kreiger PA; Lieberman SM
    Immunology; 2018 Oct; 155(2):225-237. PubMed ID: 29750331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local administration of soluble CD40:Fc to the salivary glands of non-obese diabetic mice does not ameliorate autoimmune inflammation.
    Roescher N; Vosters JL; Lai Z; Uede T; Tak PP; Chiorini JA
    PLoS One; 2012; 7(12):e51375. PubMed ID: 23300544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasmacytoid dendritic cells promote the pathogenesis of Sjögren's syndrome.
    Zhou J; Zhang X; Yu Q
    Biochim Biophys Acta Mol Basis Dis; 2022 Feb; 1868(2):166302. PubMed ID: 34780913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine concentrations in stimulated whole saliva among patients with primary Sjögren's syndrome, secondary Sjögren's syndrome, and patients with primary Sjögren's syndrome receiving varying doses of interferon for symptomatic treatment of the condition: a preliminary study.
    Streckfus C; Bigler L; Navazesh M; Al-Hashimi I
    Clin Oral Investig; 2001 Jun; 5(2):133-5. PubMed ID: 11480812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.